Literature DB >> 26620371

A crucial role for ATR in the regulation of deoxycytidine kinase activity.

Maxime Beyaert1, Eliza Starczewska1, Eric Van Den Neste2, Françoise Bontemps3.   

Abstract

Deoxycytidine kinase (dCK) (EC 2.7.1.74) is a key enzyme for salvage of deoxynucleosides and activation of numerous anticancer and antiviral nucleoside analogs. dCK activity is enhanced in response to several genotoxic treatments, which has been correlated with an increase of dCK phosphorylation at Ser-74. ATM was recently identified as the kinase responsible for Ser-74 phosphorylation and dCK activation after ionizing radiation (IR). Here, we investigated the role of ATM and the related kinase ATR in dCK activation induced by other types of DNA damage. Using ATM-deficient cells or the ATM inhibitor KU-60019, we found that ATM was not required for dCK activation caused by UV light, aphidicolin, cladribine, and unexpectedly also IR. On the other hand, the selective ATR inhibitor VE-821 significantly reduced up-regulation of dCK activity induced by these genotoxic agents, though not IR, and also down-regulated basal dCK activity. A role for ATR in the control of dCK activity was confirmed by using ATR siRNA and ATR-Seckel cells. ATR was also found to directly phosphorylate dCK at Ser-74 in vitro. Further studies revealed that ATR, which is also activated in response to IR, although later than ATM, was responsible for IR-induced dCK activation in ATM-deficient cells or in the presence of KU-60019. Overall, our results demonstrate that ATR controls basal dCK activity and dCK activation in response to replication stress and indicate that ATR can activate dCK after IR if ATM is lacking or inhibited.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATM; ATR; Aphidicolin (PubChem CID: 457964); Cladribine (PubChem CID: 20279); DNA damage; Deoxycytidine kinase; KU-60019 (PubChem CID: 15953870); Nucleoside analogs; Ser-74 phosphorylation; VE-821 (PubChem CID: 51000408)

Mesh:

Substances:

Year:  2015        PMID: 26620371     DOI: 10.1016/j.bcp.2015.11.022

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells.

Authors:  Evan R Abt; Thuc M Le; Amanda M Dann; Joseph R Capri; Soumya Poddar; Vincent Lok; Luyi Li; Keke Liang; Amanda L Creech; Khalid Rashid; Woosuk Kim; Nanping Wu; Jing Cui; Arthur Cho; Hailey Rose Lee; Ethan W Rosser; Jason M Link; Johannes Czernin; Ting-Ting Wu; Robert Damoiseaux; David W Dawson; Timothy R Donahue; Caius G Radu
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.423

2.  ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.

Authors:  Thuc M Le; Soumya Poddar; Joseph R Capri; Evan R Abt; Woosuk Kim; Liu Wei; Nhu T Uong; Chloe M Cheng; Daniel Braas; Mina Nikanjam; Peter Rix; Daria Merkurjev; Jesse Zaretsky; Harley I Kornblum; Antoni Ribas; Harvey R Herschman; Julian Whitelegge; Kym F Faull; Timothy R Donahue; Johannes Czernin; Caius G Radu
Journal:  Nat Commun       Date:  2017-08-14       Impact factor: 14.919

3.  Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function.

Authors:  Maxime Beyaert; Eliza Starczewska; Ana Cristina González Pérez; Nicolas Vanlangendonck; Pascale Saussoy; Gaëlle Tilman; Anne De Leener; Marie-Christiane Vekemans; Eric Van Den Neste; Françoise Bontemps
Journal:  Oncotarget       Date:  2017-05-24

4.  Antileukemic activity of novel adenosine derivatives.

Authors:  Anastazja Poczta; Aneta Rogalska; Małgorzata Łukawska; Agnieszka Marczak
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

5.  ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.

Authors:  Joanna Szydzik; Dan E Lind; Badrul Arefin; Yeshwant Kurhe; Ganesh Umapathy; Joachim Tetteh Siaw; Arne Claeys; Jonatan L Gabre; Jimmy Van den Eynden; Bengt Hallberg; Ruth H Palmer
Journal:  Nat Commun       Date:  2021-11-24       Impact factor: 14.919

Review 6.  Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance.

Authors:  Yuriko Saiki; Shuto Hirota; Akira Horii
Journal:  Cancer Drug Resist       Date:  2020-10-12

7.  Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.

Authors:  Eliza Starczewska; Maxime Beyaert; Lucienne Michaux; Marie-Christiane Vekemans; Pascale Saussoy; Vanesa Bol; Ainhoa Arana Echarri; Caroline Smal; Eric Van Den Neste; Françoise Bontemps
Journal:  Oncotarget       Date:  2016-06-21

8.  Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells.

Authors:  Barbora Šalovská; Hana Janečková; Ivo Fabrik; Radana Karlíková; Lucie Čecháková; Martin Ondrej; Marek Link; David Friedecký; Aleš Tichý
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.